All AbMole products are for research use only, cannot be used for human consumption.
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC).
Human AXL / UFO HEK293 Cell Line were stained with enapotamab vedotin and negative control protein respectively, washed and then followed by PE and analyzed with FACS, the EC50 is 0.16 ug/mL.
Enapotamab vedotin (2-4 mg/kg; iv, once weekly for 2 doses) inhibited the tumor growth in LU0395 xenograft mouse models.
| CAS Number | 1912424-97-5 |
| Storage | Store at ≤ -20℃ for up to 24 months. Avoid repeated freeze-thaw cycles. |
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Lorvotuzumab-MMAE
Lorvotuzumab-MMAE is an antibody-drug conjugate (ADC). |
| Anetumab-MMAE
Anetumab-MMAE is an antibody-drug conjugate (ADC). |
| Praluzatamab-MMAE
Praluzatamab-MMAE is an antibody-drug conjugate (ADC). |
| Oregovomab-MMAE
Oregovomab-MMAE is an antibody-drug conjugate (ADC). |
| Patritumab-MMAE
Patritumab-MMAE is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to MMAE. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
